MannKind Corporation at the Lytham Partners Summer 2021 Investor Conference
June 08 2021 - 5:00PM
MannKind Corporation (Nasdaq: MNKD), a company
focused on the development and commercialization of inhaled
therapeutic products for patients with endocrine and orphan lung
diseases, announced today that its Chief Executive Officer, Michael
Castagna, PharmD, will present at the Lytham Partners Summer 2021
Investor Conference on Monday, June 14, 2021 at 11:45 AM (ET).
Interested parties can access a link to the
webcast from the Events & Presentations section of the
Company's website at http://www.mannkindcorp.com. The webcast
replay will remain available for 14 days following the live
presentation.
About MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) focuses on
the development and commercialization of inhaled therapeutic
products for patients with endocrine and orphan lung diseases.
MannKind is currently commercializing Afrezza® (insulin human)
Inhalation Powder, the Company’s first FDA-approved product and the
only inhaled ultra rapid-acting mealtime insulin in the United
States, where it is available by prescription from pharmacies
nationwide. Afrezza is also available by prescription
in Brazil where it is commercialized by the Company’s
partner Biomm SA. MannKind was established in 1991,
and is headquartered in Westlake Village, California, with a
manufacturing and R&D facility in Danbury, Connecticut. The
Company also employs field sales and medical representatives across
the U.S. Please visit www.mannkindcorp.com to learn more.
Contact:818-661-5000ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Jun 2024 to Jul 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Jul 2023 to Jul 2024